Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
figureposted on 2020-12-01, 16:55 authored by Ana-Maria Orbai, Jordi Gratacós, Anthony Turkiewicz, Stephen Hall, Eva Dokoupilova, Bernard Combe, Peter Nash, Gaia Gallo, Clinton C. Bertram, Amanda M. Gellett, Aubrey Trevelin Sprabery, Julie Birt, Lisa Macpherson, Vladimir J. Geneus, Arnaud Constantin
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.